74 studies on Glucagon agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The impressive 24% body weight reduction observed with retatrutide represents a significant leap forward in obesity pharmacotherapy, potentially offering efficacy comparable to bariatric surgery for some individuals. …
This study provides compelling evidence that dual and triple incretin agonists offer superior glycemic control and weight loss benefits compared to current GLP-1 receptor agonists for patients with Type 2 Diabetes. Th…
This study highlights the potential of retatrutide to not only manage blood glucose but also to directly address the underlying appetite dysregulation in type 2 diabetes and obesity. By improving appetite control and …
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
These advancements collectively represent a significant leap forward in nephrology, offering new hope for patients with various kidney conditions. The expansion of complement inhibitors and the efficacy of GLP-1 recep…
This perspective highlights that Retatrutide exemplifies rational multi-agonist peptide engineering, signaling a paradigm shift in systems pharmacology for obesity and related conditions. Its unprecedented efficacy su…
This review underscores the transformative potential of multi-target incretin-based therapeutics for metabolic disorders. These agents could significantly expand the therapeutic arsenal for patients struggling with ty…
The findings from this Phase 1 study are critically important for the future development of LY3437943. Understanding the impact of hepatic impairment on drug pharmacokinetics is essential for establishing safe and eff…
This review highlights a rapidly evolving therapeutic landscape for MASLD in T2D, moving towards integrated metabolic, hepatic, and cardiovascular risk reduction. The identification of agents like semaglutide and resm…